Cargando…

Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population

The increasing prevalence of Alzheimer’s disease (AD) has become a global phenomenon presenting serious social and health challenges. For detecting early molecular changes in the disease, several techniques to measure varied species of amyloid beta in the peripheral blood have been recently develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Ju, Choi, Youngki, Chung, Soie, Yoon, Dae Hyun, Choi, Seung Ho, Kang, Sung-Min, Seo, David, Park, Kyung-Il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236003/
https://www.ncbi.nlm.nih.gov/pubmed/32326061
http://dx.doi.org/10.3390/diagnostics10040237
_version_ 1783536080117563392
author Lee, Jung-Ju
Choi, Youngki
Chung, Soie
Yoon, Dae Hyun
Choi, Seung Ho
Kang, Sung-Min
Seo, David
Park, Kyung-Il
author_facet Lee, Jung-Ju
Choi, Youngki
Chung, Soie
Yoon, Dae Hyun
Choi, Seung Ho
Kang, Sung-Min
Seo, David
Park, Kyung-Il
author_sort Lee, Jung-Ju
collection PubMed
description The increasing prevalence of Alzheimer’s disease (AD) has become a global phenomenon presenting serious social and health challenges. For detecting early molecular changes in the disease, several techniques to measure varied species of amyloid beta in the peripheral blood have been recently developed, but the efforts to associate them with cognitive assessments have yet to produce sufficient data. We prospectively collected participants from the consecutive population who visited our center for brain health screening. In total, 97 participants (F:M = 58:39) aged 69.4 ± 7.52 were assessed. Participants performed the Korean version of the Consortium to Establish a Registry for Alzheimer’s disease (CERAD-K), the clinical dementia rating (CDR), plasma oligomeric amyloid-β (OAβ) level tests, routine blood tests, ApoE genotype, and brain MRI. Among total population, 55.7% had a CDR of 0, and 40.2% had a CDR of 0.5. The results showed that word memory and word recall, and the total scores of the CERAD-K were negatively correlated with the plasma OAβ level. With a cut-off value of 0.78 ng/mL for the OAβ level and a −1.5 standard deviation of age/sex/education adjusted norms for the CERAD-K; naming, word memory, word recall, word recognition, and total score were significantly correlated with the OAβ level. No correlation between the OAβ level and mini-mental status examination was found. Our results demonstrate that the level of plasma OAβ was well correlated with the measure of cognitive function through the CERAD-K in the field data collected from consecutive populations. Studies on longitudinal comparisons with large cohorts will further validate the diagnostic value of plasma OAβ as a useful biomarker for screening AD and predicting progression.
format Online
Article
Text
id pubmed-7236003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72360032020-05-28 Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population Lee, Jung-Ju Choi, Youngki Chung, Soie Yoon, Dae Hyun Choi, Seung Ho Kang, Sung-Min Seo, David Park, Kyung-Il Diagnostics (Basel) Article The increasing prevalence of Alzheimer’s disease (AD) has become a global phenomenon presenting serious social and health challenges. For detecting early molecular changes in the disease, several techniques to measure varied species of amyloid beta in the peripheral blood have been recently developed, but the efforts to associate them with cognitive assessments have yet to produce sufficient data. We prospectively collected participants from the consecutive population who visited our center for brain health screening. In total, 97 participants (F:M = 58:39) aged 69.4 ± 7.52 were assessed. Participants performed the Korean version of the Consortium to Establish a Registry for Alzheimer’s disease (CERAD-K), the clinical dementia rating (CDR), plasma oligomeric amyloid-β (OAβ) level tests, routine blood tests, ApoE genotype, and brain MRI. Among total population, 55.7% had a CDR of 0, and 40.2% had a CDR of 0.5. The results showed that word memory and word recall, and the total scores of the CERAD-K were negatively correlated with the plasma OAβ level. With a cut-off value of 0.78 ng/mL for the OAβ level and a −1.5 standard deviation of age/sex/education adjusted norms for the CERAD-K; naming, word memory, word recall, word recognition, and total score were significantly correlated with the OAβ level. No correlation between the OAβ level and mini-mental status examination was found. Our results demonstrate that the level of plasma OAβ was well correlated with the measure of cognitive function through the CERAD-K in the field data collected from consecutive populations. Studies on longitudinal comparisons with large cohorts will further validate the diagnostic value of plasma OAβ as a useful biomarker for screening AD and predicting progression. MDPI 2020-04-20 /pmc/articles/PMC7236003/ /pubmed/32326061 http://dx.doi.org/10.3390/diagnostics10040237 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Jung-Ju
Choi, Youngki
Chung, Soie
Yoon, Dae Hyun
Choi, Seung Ho
Kang, Sung-Min
Seo, David
Park, Kyung-Il
Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title_full Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title_fullStr Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title_full_unstemmed Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title_short Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population
title_sort association of plasma oligomerized beta amyloid with neurocognitive battery using korean version of consortium to establish a registry for alzheimer’s disease in health screening population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236003/
https://www.ncbi.nlm.nih.gov/pubmed/32326061
http://dx.doi.org/10.3390/diagnostics10040237
work_keys_str_mv AT leejungju associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT choiyoungki associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT chungsoie associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT yoondaehyun associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT choiseungho associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT kangsungmin associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT seodavid associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation
AT parkkyungil associationofplasmaoligomerizedbetaamyloidwithneurocognitivebatteryusingkoreanversionofconsortiumtoestablisharegistryforalzheimersdiseaseinhealthscreeningpopulation